-
1.发明公开Dosages for treatment of anti-erbB2 antibodies 审中-公开Dosierungfürdie Behandlung mit Anti-ErbB2-Antikörpern
公开(公告)号：EP2110138A1
公开(公告)日：2009-10-21
申请号：EP09008314.8
申请日：2000-08-25
申请人： Genentech, Inc.
IPC分类号： A61K39/395 , C07K16/32
CPC分类号： C07K16/30 , A61K31/337 , A61K38/00 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K16/32 , A61K2300/00
摘要： The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
摘要翻译： 本发明涉及以ErbB2过度表达为特征的疾病的治疗。 更具体地，本发明涉及用抗ErbB2抗体治疗易患或被诊断患有过度表达ErbB2的癌细胞的人类患者。
-
公开(公告)号：EP0853121A3
公开(公告)日：1998-08-05
申请号：EP98105190.7
申请日：1989-12-20
申请人： Genentech, Inc.
发明人： Shak, Steven
CPC分类号： C12Q1/6876 , A61K38/00 , C12N9/22 , C12N11/08 , C12N15/71 , C12N15/85 , C12N2800/108 , C12N2830/42 , C12N2840/44
摘要： DNA isolates coding for human DNase and methods of obtaining such DNA are provided, together with expression systems for recombinant production of human DNase useful in therapeutic or diagnostic compositions.
摘要翻译： 提供了编码人DNA酶的DNA分离物和获得这种DNA的方法，以及用于重组生产用于治疗或诊断组合物的人DNase的表达系统。
-
公开(公告)号：EP2275450A1
公开(公告)日：2011-01-19
申请号：EP10177992.4
申请日：1998-12-10
申请人： Genentech, Inc.
IPC分类号： C07K16/32 , A61K39/395
CPC分类号： A61K31/337 , A61K31/7068 , A61K38/00 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/32 , C07K2317/24 , A61K31/335 , A61K2300/00
摘要： The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
摘要翻译： 本发明涉及以ErbB2过度表达为特征的疾病的治疗。 更具体地，本发明涉及用抗ErbB2抗体和除蒽环类化合物之外的化学治疗剂的组合治疗对过度表达ErbB2的癌细胞敏感或诊断的人类患者。 多柔比星或表柔比星。
-
公开(公告)号：EP0372752A3
公开(公告)日：1990-07-04
申请号：EP89312131.9
申请日：1989-11-22
申请人： GENENTECH, INC.
CPC分类号： A61K38/1774 , A61K47/58 , A61K47/60 , A61K47/61
摘要： Novel conjugates of CD4 and a nonproteinaceous polymer such as polyethylene glycol exhibit improved therapeutic and physicochemical characteristics, most notably an extended biological half-life. The conjugates are useful in the treatment of HIV infections.
-
5.发明公开Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent 审中-公开用针对ERBB2和化学治疗剂治疗癌症
公开(公告)号：EP1947119A3
公开(公告)日：2012-12-19
申请号：EP08002425.0
申请日：1998-12-10
申请人： Genentech, Inc.
IPC分类号： C07K16/32 , A61K39/395
CPC分类号： C07K16/32 , A61K38/00 , A61K39/39558 , A61K2039/505 , C07K2317/24 , A61K2300/00
摘要： The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
-
公开(公告)号：EP2277919A1
公开(公告)日：2011-01-26
申请号：EP10178009.6
申请日：1998-12-10
申请人： Genentech, Inc.
IPC分类号： C07K16/32 , A61K39/395
CPC分类号： A61K31/337 , A61K31/7068 , A61K38/00 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/32 , C07K2317/24 , A61K31/335 , A61K2300/00
摘要： The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and gemcitabine.
摘要翻译： 本发明涉及以ErbB2过度表达为特征的疾病的治疗。 更具体地说，本发明涉及用抗ErbB2抗体和吉西他滨的组合治疗易患或诊断为过度表达ErbB2的癌症的人类患者。
-
7.发明公开Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent 审中-公开Krebsbehandlung mitAntikörperngegen ERBB2和einem chemotherapeutischen Mittel
公开(公告)号：EP1947119A2
公开(公告)日：2008-07-23
申请号：EP08002425.0
申请日：1998-12-10
申请人： Genentech, Inc.
IPC分类号： C07K16/32 , A61K39/395 , A61K31/335
CPC分类号： C07K16/32 , A61K38/00 , A61K39/39558 , A61K2039/505 , C07K2317/24 , A61K2300/00
摘要： The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
摘要翻译： 本发明涉及以ErbB2过度表达为特征的疾病的治疗。 更具体地，本发明涉及用抗ErbB2抗体和除蒽环类化合物之外的化学治疗剂的组合治疗对过度表达ErbB2的癌细胞敏感或诊断的人类患者。 多柔比星或表柔比星。
-
公开(公告)号：EP0853121B1
公开(公告)日：2007-03-28
申请号：EP98105190.7
申请日：1989-12-20
申请人： GENENTECH, INC.
发明人： Shak, Steven
IPC分类号： C12N9/22
CPC分类号： C12Q1/6876 , A61K38/00 , C12N9/22 , C12N11/08 , C12N15/71 , C12N15/85 , C12N2800/108 , C12N2830/42 , C12N2840/44
-
公开(公告)号：EP2111870A1
公开(公告)日：2009-10-28
申请号：EP09008313.0
申请日：2000-08-25
申请人： Genentech, Inc.
IPC分类号： A61K39/395 , C07K16/32
CPC分类号： C07K16/30 , A61K31/337 , A61K38/00 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K16/32 , A61K2300/00
摘要： The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.
摘要翻译： 本发明涉及治疗以ErbB2的过表达为特征的病症。 更具体地说，本发明涉及用抗ErbB2抗体治疗易患或诊断患有过度表达ErbB2的癌症的人类患者。
-
公开(公告)号：EP1980618A2
公开(公告)日：2008-10-15
申请号：EP08005896.9
申请日：1996-02-21
申请人： Genentech, Inc.
发明人： Lazarus, Robert A. , Shak, Steven , Ulmer, Jana S.
CPC分类号： C12N9/22
摘要： The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of action-resistant variants of human DNase I.
摘要翻译： 本发明涉及具有降低的对肌动蛋白的结合亲和力的人类DNA酶I的氨基酸序列变体。 本发明提供了编码这种肌动蛋白抗性变体的核酸序列，从而能够以足以临床使用的量生产这些变体。 本发明还涉及药物组合物和人类DNA酶I的作用抗性变体的治疗用途。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.014 秒)
